Orion Oyj Series A | Balance Sheet

Fiscal year is January-December. All values EUR Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
215
259
245
232
164
284
Total Accounts Receivable
197
204
204
215
216
206
Inventories
196
179
206
228
225
222
Other Current Assets
22
11
19
18
15
16
Total Current Assets
630
652
674
691
621
728
Net Property, Plant & Equipment
247
269
276
289
323
317
Total Investments and Advances
-
3
9
10
1
-
Long-Term Note Receivable
-
-
4
4
2
1
Intangible Assets
71
64
58
54
53
64
Other Assets
27
-
24
23
55
32
Total Assets
979
1,002
1,047
1,063
1,056
1,147
ST Debt & Current Portion LT Debt
25
25
10
2
1
Accounts Payable
60
67
99
106
83
Income Tax Payable
2
1
1
15
3
Other Current Liabilities
111
123
123
108
92
Total Current Liabilities
198
215
233
231
180
Long-Term Debt
233
210
178
150
150
Provision for Risks & Charges
2
32
3
4
4
Deferred Taxes
31
23
37
36
41
Other Liabilities
-
-
1
-
-
Total Liabilities
465
487
453
422
376
Common Equity (Total)
514
515
595
641
680
Total Shareholders' Equity
514
515
595
641
680
Total Equity
514
515
595
641
680
Liabilities & Shareholders' Equity
979
1,002
1,047
1,063
1,056

About Orion Oyj

View Profile
Address
Orionintie 1A
Espoo UU 02200
Finland
Employees -
Website http://www.orion.fi
Updated 07/08/2019
Orion Oyj engages in the development of pharmaceutical and diagnostic test. It develops, manufactures, and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Its pharmaceutical research and development focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler pulmonary drugs.